D. Ahmadvand, M. J. Rasaee, F. Rahbarizadeh, R. E. Kontermann, and F. Sheikholislami, Cell selection and characterization of a novel human endothelial cell specific nanobody, Molecular Immunology, vol.46, issue.8-9, pp.8-9, 2009.
DOI : 10.1016/j.molimm.2009.01.021

A. Ghahroudi, M. Desmyter, A. Wyns, L. Hamers, R. Muyldermans et al., Selection and identification of single domain antibody fragments from camel heavy-chain antibodies, FEBS Letters, vol.15, issue.3, pp.521-526, 1997.
DOI : 10.1016/S0014-5793(97)01062-4

M. V. Backer and J. M. Backer, Targeting Endothelial Cells Overexpressing VEGFR-2:?? Selective Toxicity of Shiga-like Toxin???VEGF Fusion Proteins, Bioconjugate Chemistry, vol.12, issue.6, pp.1066-1073, 2001.
DOI : 10.1021/bc015534j

P. Bhargava and M. O. Robinson, Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status, Current Oncology Reports, vol.9, issue.2, pp.103-111, 2011.
DOI : 10.1007/s11912-011-0154-3

T. Boldicke, H. Weber, P. P. Mueller, B. Barleon, and M. Bernal, Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR), Journal of Immunological Methods, vol.300, issue.1-2, pp.1-2, 2005.
DOI : 10.1016/j.jim.2005.03.007

C. J. Bond, J. C. Marsters, and S. S. Sidhu, Contributions of CDR3 to VHH Domain Stability and the Design of Monobody Scaffolds for Naive Antibody Libraries, Journal of Molecular Biology, vol.332, issue.3, pp.643-655, 2003.
DOI : 10.1016/S0022-2836(03)00967-7

K. Buelens, G. Hassanzadeh-ghassabeh, S. Muyldermans, A. Gils, and P. J. Declerck, Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor, Journal of Thrombosis and Haemostasis, vol.283, issue.6, pp.1302-1312, 2010.
DOI : 10.1111/j.1538-7836.2010.03816.x

K. E. Conrath, M. Lauwereys, M. Galleni, A. Matagne, J. M. Frere et al., Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae, Antimicrob. Agents Chemother, issue.10, pp.45-2807, 2001.

M. Dougher-vermazen, J. D. Hulmes, P. Bohlen, and B. I. Terman, Biological Activity and Phosphorylation Sites of the Bacterially Expressed Cytosolic Domain of the KDR VEGF-Receptor, Biochemical and Biophysical Research Communications, vol.205, issue.1, pp.728-738, 1994.
DOI : 10.1006/bbrc.1994.2726

P. J. Doyle, M. Arbabi-ghahroudi, N. Gaudette, G. Furzer, M. E. Savard et al., Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol, Molecular Immunology, vol.45, issue.14, pp.45-3703, 2008.
DOI : 10.1016/j.molimm.2008.06.005

L. M. Ellis and D. J. Hicklin, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nature Reviews Cancer, vol.119, issue.8, pp.579-591, 2008.
DOI : 10.1038/nrc2403

N. Ferrara, VEGF-A: a critical regulator of blood vessel growth, Eur. Cytokine Netw, vol.20, issue.4, pp.158-163, 2009.

J. Folkman, Anti-Angiogenesis, Annals of Surgery, vol.175, issue.3, pp.409-416, 1972.
DOI : 10.1097/00000658-197203000-00014

J. Folkman, Angiogenesis: an organizing principle for drug discovery?, Nature Reviews Drug Discovery, vol.57, issue.5, pp.273-286, 2007.
DOI : 10.1038/nrd2115

E. R. Goldman, G. P. Anderson, J. L. Liu, J. B. Delehanty, L. J. Sherwood et al., Facile Generation of Heat-Stable Antiviral and Antitoxin Single Domain Antibodies from a Semisynthetic Llama Library, Analytical Chemistry, vol.78, issue.24, pp.78-8245, 2006.
DOI : 10.1021/ac0610053

I. Hmila, D. Saerens, B. Abderrazek, R. Vincke, C. Abidi et al., A bispecific nanobody to provide full protection against lethal scorpion envenoming, The FASEB Journal, vol.24, issue.9, pp.3479-3489, 2010.
DOI : 10.1096/fj.09-148213

URL : https://hal.archives-ouvertes.fr/pasteur-00612182

K. Holmes, O. L. Roberts, A. M. Thomas, and M. J. Cross, Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition, Cellular Signalling, vol.19, issue.10, pp.2003-2012, 2007.
DOI : 10.1016/j.cellsig.2007.05.013

J. Huang, Y. Tan, Q. Tang, X. Liu, X. Guan et al., A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes, Cytotechnology, vol.17, issue.1, pp.61-71, 2010.
DOI : 10.1007/s10616-010-9262-4

J. Kendrew, C. Eberlein, B. Hedberg, K. Mcdaid, N. R. Smith et al., An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2-Dependent Angiogenesis without Affecting Ligand Binding, Molecular Cancer Therapeutics, vol.10, issue.5, pp.770-783, 2011.
DOI : 10.1158/1535-7163.MCT-10-0876

B. Kou, Y. Li, L. Zhang, G. Zhu, X. Wang et al., In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment, Experimental and Molecular Pathology, vol.76, issue.2, pp.129-137, 2004.
DOI : 10.1016/j.yexmp.2003.10.010

S. V. Kozin, Y. Boucher, D. J. Hicklin, P. Bohlen, R. K. Jain et al., Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiationinduced long-term control of human tumor xenografts, Cancer Res, vol.61, issue.1, pp.39-44, 2001.

P. Lafaye, I. Achour, P. England, C. Duyckaerts, and F. Rougeon, Single-domain antibodies recognize selectively small oligomeric forms of amyloid ??, prevent A??-induced neurotoxicity and inhibit fibril formation, Molecular Immunology, vol.46, issue.4, pp.695-704, 2009.
DOI : 10.1016/j.molimm.2008.09.008

M. P. Lefranc, C. Pommie, Q. Kaas, E. Duprat, N. Bosc et al., IMGT unique numbering for immunoglobulin and T cell receptor constant domains and Ig superfamily C-like domains, Developmental & Comparative Immunology, vol.29, issue.3, pp.185-203, 2005.
DOI : 10.1016/j.dci.2004.07.003

D. Lu, X. Jimenez, H. Zhang, P. Bohlen, L. Witte et al., Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy, International Journal of Cancer, vol.19, issue.3, pp.393-399, 2002.
DOI : 10.1002/ijc.1634

M. Meissner, M. Doll, I. Hrgovic, G. Reichenbach, V. Konig et al., Suppression of VEGFR2 Expression in Human Endothelial Cells by Dimethylfumarate Treatment: Evidence for Anti-Angiogenic Action, Journal of Investigative Dermatology, vol.131, issue.6, pp.1356-1364, 2011.
DOI : 10.1038/jid.2011.46

H. Q. Miao, K. Hu, X. Jimenez, E. Navarro, H. Zhang et al., Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2, Biochemical and Biophysical Research Communications, vol.345, issue.1, pp.438-445, 2006.
DOI : 10.1016/j.bbrc.2006.04.119

S. Muyldermans, Single domain camel antibodies: current status, Reviews in Molecular Biotechnology, vol.74, issue.4, pp.277-302, 2001.
DOI : 10.1016/S1389-0352(01)00021-6

S. Muyldermans, T. N. Baral, V. C. Retamozzo, P. De-baetselier, E. De-genst et al., Camelid immunoglobulins and nanobody technology, Veterinary Immunology and Immunopathology, vol.128, issue.1-3, pp.1-3, 2009.
DOI : 10.1016/j.vetimm.2008.10.299

S. Oliveira, R. M. Schiffelers, J. Van-der-veeken, R. Van-der-meel, R. Vongpromek et al., Downregulation of EGFR by a novel multivalent nanobody-liposome platform, Journal of Controlled Release, vol.145, issue.2, pp.165-175, 2010.
DOI : 10.1016/j.jconrel.2010.03.020

A. K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-welsh, VEGF receptor signalling ??? in control of vascular function, Nature Reviews Molecular Cell Biology, vol.99, issue.5, pp.359-371, 2006.
DOI : 10.1038/nrm1911

K. Omidfar, M. J. Rasaee, H. Modjtahedi, M. Forouzandeh, M. Taghikhani et al., Production and Characterization of a New Antibody Specific for the Mutant EGF Receptor, EGFRvIII, in <i>Camelus bactrianus</i>, Tumor Biology, vol.13, issue.4, pp.179-187, 2004.
DOI : 10.1002/ijc.10189

F. Rahbarizadeh, D. Ahmadvand, and Z. Sharifzadeh, Nanobody; an Old Concept and New Vehicle for Immunotargeting, Immunological Investigations, vol.42, issue.28, pp.299-338, 2011.
DOI : 10.1016/S0001-2998(97)80033-5

F. Rahbarizadeh, M. J. Rasaee, F. Moghadam, M. Allameh, A. A. Sadroddiny et al., Production of Novel Recombinant Single-Domain Antibodies against Tandem Repeat Region of MUC1 Mucin, Hybridoma and Hybridomics, vol.23, issue.3, pp.151-159, 2004.
DOI : 10.1089/1536859041224334

D. Ribatti, The Discovery of Antiangiogenic Molecules: A Historical Review, Current Pharmaceutical Design, vol.15, issue.4, pp.345-352, 2009.
DOI : 10.2174/138161209787315855

R. C. Roovers, T. Laeremans, L. Huang, S. De-taeye, A. J. Verkleij et al., Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies, Cancer Immunology, Immunotherapy, vol.2, issue.11, pp.303-317, 2007.
DOI : 10.1007/s00262-006-0180-4

R. Jr and R. , VEGF receptor protein-tyrosine kinases: structure and regulation, Biochem. Biophys. Res. Commun, vol.375, issue.3, pp.287-291, 2008.

D. Saerens, G. H. Ghassabeh, and S. Muyldermans, Single-domain antibodies as building blocks for novel therapeutics, Current Opinion in Pharmacology, vol.8, issue.5, pp.600-608, 2008.
DOI : 10.1016/j.coph.2008.07.006

J. Spratlin, Ramucirumab (IMC-1121B): Monoclonal Antibody Inhibition of Vascular Endothelial Growth Factor Receptor-2, Current Oncology Reports, vol.17, issue.3, pp.97-102, 2011.
DOI : 10.1007/s11912-010-0149-5

J. L. Spratlin, R. B. Cohen, M. Eadens, L. Gore, D. R. Camidge et al., Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2, pp.780-787, 2010.
DOI : 10.1200/JCO.2009.23.7537

J. L. Spratlin, K. E. Mulder, and J. R. Mackey, Ramucirumab (IMC-1121B): a novel attack on angiogenesis, Future Oncology, vol.6, issue.7, pp.1085-1094, 2010.
DOI : 10.2217/fon.10.75

K. Tamura, D. Peterson, N. Peterson, G. Stecher, M. Nei et al., MEGA5: Molecular Evolutionary Genetics Analysis Using Maximum Likelihood, Evolutionary Distance, and Maximum Parsimony Methods, Molecular Biology and Evolution, vol.28, issue.10, pp.28-2731, 2011.
DOI : 10.1093/molbev/msr121

B. Thys, L. Schotte, S. Muyldermans, U. Wernery, G. Hassanzadeh-ghassabeh et al., In vitro antiviral activity of single domain antibody fragments against poliovirus, Antiviral Research, vol.87, issue.2, pp.257-264, 2010.
DOI : 10.1016/j.antiviral.2010.05.012

G. Veggiani, G. Ossolengo, M. Aliprandi, U. Cavallaro, and A. De-marco, Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1, Biochemical and Biophysical Research Communications, vol.408, issue.4, pp.692-696, 2011.
DOI : 10.1016/j.bbrc.2011.04.090

H. Watanabe, A. J. Mamelak, E. Weiss, B. Wang, I. Freed et al., Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model, Clin. Cancer Res, vol.11, issue.1, pp.407-409, 2005.

H. Youssoufian, D. J. Hicklin, and E. K. Rowinsky, Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy, Clinical Cancer Research, vol.13, issue.18, pp.5544-5548, 2007.
DOI : 10.1158/1078-0432.CCR-07-1107

J. Zhang, P. L. Yang, and N. S. Gray, Targeting cancer with small molecule kinase inhibitors, Nature Reviews Cancer, vol.62, issue.1, pp.28-39, 2009.
DOI : 10.1016/S0092-8674(03)00194-6